Evidence map›Paper›PMID 36108149›Full record

ArticleBlood cancer discovery2023

Extracellular Vesicle Secretion by Leukemia Cells In Vivo Promotes CLL Progression by Hampering Antitumor T-cell Responses.

Ernesto Gargiulo, Elodie Viry, Pablo Elías Morande, Anne Largeot, Susanne Gonder, Feng Xian, Nikolaos Ioannou, Mohaned Benzarti, Felix Bruno Kleine Borgmann, Michel Mittelbronn and 7 more

Open access · hybridAbstract readEditorial
In one paragraph

Article in Blood cancer discovery, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 4 countries.

Ernesto GargiuloTumor-Stroma Interactions Group, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg City, Luxembourg.ORCID 0000-0002-4485-4599
Elodie ViryTumor-Stroma Interactions Group, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg City, Luxembourg.ORCID 0000-0002-1226-1473
Pablo Elías MorandeTumor-Stroma Interactions Group, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg City, Luxembourg.ORCID 0000-0002-2559-1906
Anne LargeotTumor-Stroma Interactions Group, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg City, Luxembourg.ORCID 0000-0002-9388-8461
Susanne GonderTumor-Stroma Interactions Group, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg City, Luxembourg.ORCID 0000-0001-7582-6905
Feng XianProteomics of Cellular Signaling, Department of Infection and Immunity, Luxembourg Institute of Health, Strassen, Luxembourg.ORCID 0000-0002-8345-0108
Nikolaos IoannouSchool of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom.ORCID 0000-0002-7956-5543
Mohaned BenzartiFaculty of Science, Technology and Medicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg.ORCID 0000-0002-6413-3983
Felix Bruno Kleine BorgmannFaculty of Science, Technology and Medicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg.
Michel MittelbronnFaculty of Science, Technology and Medicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg.ORCID 0000-0002-2998-052X
Gunnar DittmarFaculty of Science, Technology and Medicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg.ORCID 0000-0003-3647-8623
Petr V NazarovMultiomics Data Science Group, Department of Cancer Research, Luxembourg Institute of Health, Strassen, Luxembourg.ORCID 0000-0003-3443-0298
Johannes MeiserCancer Metabolism Group, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg City, Luxembourg.ORCID 0000-0002-9093-6210
Basile StamatopoulosLabora-tory of Clinical Cell Therapy, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium.ORCID 0000-0002-0580-7394
Alan G RamsaySchool of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom.ORCID 0000-0002-0452-0420
Etienne Moussay *Tumor-Stroma Interactions Group, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg City, Luxembourg.ORCID 0000-0002-0879-8067
Jérôme Paggetti *Tumor-Stroma Interactions Group, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg City, Luxembourg.ORCID 0000-0001-9460-5876
Luxembourg Institute of Health · LUUniversity of Luxembourg · LUKing's College London · GBAcademia Nacional de Medicina · ARCentre Hospitalier de Luxembourg · LUInstitut Jules Bordet · BE

Funding

European Commission (EC) H2020-MSCA-IF-2020: 101029602Fonds De La Recherche Scientifique - FNRS (FNRS) 7.4503.19Fonds De La Recherche Scientifique - FNRS (FNRS) 7.4509.20Fonds De La Recherche Scientifique - FNRS (FNRS) 7.6604.21Fonds De La Recherche Scientifique - FNRS (FNRS) 7.8506.19Fonds National de la Recherche Luxembourg (FNR) A18/BM/11809970Fonds National de la Recherche Luxembourg (FNR) C20/BM/14582635Fonds National de la Recherche Luxembourg (FNR) C20/BM/14592342Fonds National de la Recherche Luxembourg (FNR) INTER/DFG/16/11509946Fonds National de la Recherche Luxembourg (FNR) P16/BM/11192868Fonds National de la Recherche Luxembourg (FNR) PRIDE15/10675146/CANBIO
6 · The paper itself

Abstract

Small extracellular vesicle (sEV, or exosome) communication among cells in the tumor microenvironment has been modeled mainly in cell culture, whereas their relevance in cancer pathogenesis and progression in vivo is less characterized. Here we investigated cancer-microenvironment interactions in vivo using mouse models of chronic lymphocytic leukemia (CLL). sEVs isolated directly from CLL tissue were enriched in specific miRNA and immune-checkpoint ligands. Distinct molecular components of tumor-derived sEVs altered CD8+ T-cell transcriptome, proteome, and metabolome, leading to decreased functions and cell exhaustion ex vivo and in vivo. Using antagomiRs and blocking antibodies, we defined specific cargo-mediated alterations on CD8+ T cells. Abrogating sEV biogenesis by Rab27a/b knockout dramatically delayed CLL pathogenesis. This phenotype was rescued by exogenous leukemic sEV or CD8+ T-cell depletion. Finally, high expression of sEV-related genes correlated with poor outcomes in CLL patients, suggesting sEV profiling as a prognostic tool. In conclusion, sEVs shape the immune microenvironment during CLL progression. SIGNIFICANCE: sEVs produced in the leukemia microenvironment impair CD8+ T-cell mediated antitumor immune response and are indispensable for leukemia progression in vivo in murine preclinical models. In addition, high expression of sEV-related genes correlated with poor survival and unfavorable clinical parameters in CLL patients. See related commentary by Zhong and Guo, p. 5. This article is highlighted in the In This Issue feature, p. 1.

Indexed as

Extracellular VesiclesLeukemia, Lymphocytic, Chronic, B-CellAnimalsCD8-Positive T-LymphocytesImmunityMiceTranscriptomeTumor Microenvironment

Identifiers

PMID36108149
PMCPMC9816815
OpenAlexW4295932262

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.